Lung Diseases clinical trials at UC Health
3 research studies open to new patients

• A Study of the Safety of Experimental CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis (decreased lung function)

  “The purpose of this study is to test an experimental drug called CC-90001 in patients with Idiopathic pulmonary fibrosis (IPF).”

  open to eligible people ages 40 years and up

  This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment doses of CC-90001, 200 mg and 400 mg, compared with placebo, when delivered once daily per os (PO) in subjects with idiopathic pulmonary fibrosis (IPF). This study is designed to assess response to treatment by using measures of lung function, disease progression, fibrosis on radiography, and patient-reported outcomes. It will also assess dose response.

  at UC Davis

• Heart and Lung Function Monitoring System

  open to eligible people ages 18 years and up

  The investigator goal is to test a new device to see if it can provide continuous and simultaneous monitoring of heart and lung function.

  at UCLA

• TandemHeart Experiences and MEthods (THEME Registry)

  open to eligible people ages 18 years and up

  This study is intended to be a multicenter, prospective observation registry. By collecting prospective descriptive data, provide insight into disease defining characteristics resulting in the clinical decision to use TandemHeart for mechanical support and enhance knowledge of best practice regarding clinical management, weaning and removal/exit strategies.

  at UCSD

Last updated: April 3, 2019